Concurrent occurrence of BCR::ABL1-positive chronic myeloid leukaemia and Philadelphia-negative myeloproliferative neoplasm
Súčasný výskyt BCR::ABL1 pozitívnej chronickej myelocytovej leukémie a Ph-negatívneho myeloproliferatívneho ochorenia
Chronická myelocytová leukémia (CML) sa vďaka liečbe inhibítormi tyrozinkináz (TKI) stala za posledné dve desaťročia dobre liečiteľným onkohematologickým ochorením pre väčšinu našich pacientov. Ich celkové prežívanie je porovnateľné s prežívaním tzv. bežnej populácie a CML je príčinou úmrtia len malej skupiny pacientov, ktorí sú rezistentní na viaceré TKI. Priaznivú prognózu pacientov s CML však môže okrem rezistencie na TKI negatívne ovplyvniť sekundárne malígne ochorenie alebo duplicitné klonálne ochorenie kostnej drene. V našom príspevku prezentujeme tri prípady pacientov s CML, u ktorých bolo diagnostikované aj Ph negatívne myeloproliferatívne ochorenie. Okrem našich skúseností s manažmentom týchto pacientov sa v článku zaoberáme aj prehľadom literatúry s touto problematikou.
Klíčová slova:
myelofibróza – chronická myelocytová leukémia – inhibítory tyrozinkinázy – ruxolitinib – splenomegália
Authors:
K. Slezáková 1; Z. Sninská 1; A. Bátorová 1; A. Žákovičová 2; R. Lukačková 2; Ľ. Majerová 2; J. Marcinek 3; P. Szépe 3; L. Plank 3; K. Rejlekova 4
Authors‘ workplace:
Klinika hematológie a transfúziológie LFUK a UNB
1; Medirex a. s.
2; Univerzitná nemocnica Martin
3; II. onkologická klinika LF UK a NOÚ
4
Published in:
Transfuze Hematol. dnes,32, 2026, No. Ahead of Print, p. 1-6.
Category:
Case Reports
doi:
https://doi.org/10.48095/cctahd202607
Overview
Chronic myeloid leukemia (CML) has become a treatable onco-hematological disease for most of our patients over the past two decades, thanks to tyrosinkinase inhibitors. Their overall survival is comparable to that of the general population and CML is the cause of death in only a small group of patients who are resistant to multiple TKIs. However, the favorable prognosis of CML patients may be negatively affected by secondary malignancy or duplicate clonal bone marrow disease, in addition to TKI resistance. We present a detailed description of clinical, cytomorphological and molecular characteristics of 3 CML patients with coexiting Ph negative myeloproliferative disorders with driver mutations. This article also provides a review of the literature on this issue.
Keywords:
chronic myeloid leukaemia – myelofibrosis – Splenomegaly – tyrosinkinase inhibitors – ruxolitinib
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2026 Issue Ahead of Print
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
- Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
- Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
Most read in this issue
- Venetoclax plus azacitidine as a bridge treatment to allogeneic stem cell transplantation in acute myeloid leukaemia patients
- Acute myeloid leukemia – how the approach to diagnosis, risk stratification, and treatment options has changed
- Recommendation of the Society for Transfusion Medicine No. 20 Cold red blood cell antibodies testing before cardiothoracic surgery on cardiopulmonary bypass
- Antifungal prophylaxis in patients with acute myeloid leukaemia treated with venetoclax and azacitidine